Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPERIUM: Glucose-Dependent vs Reference Strategy in Older T2DM
NCT02072096Phase 4Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2014
- Primary completion
- Oct 2015
- Countries
- 5
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia at 72 weeks. Started Feb 2014; status: terminated.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02072096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072096.